Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry.

PMID:30144306
MacKenzie-Graham A , Brook J , Kurth F , Itoh Y , Meyer C , Montag MJ , Wang HJ , Elashoff R , Voskuhl RR
Progressive gray matter (GM) atrophy is a hallmark of multiple sclerosis (MS). Cognitive impairment has been observed in 40%-70% of MS patients and has been linked to GM atrophy. In a phase 2 trial of estriol treatment in women with relapsing-remitting MS (RRMS), higher estriol levels correlated with greater improvement on the paced auditory serial addition test (PASAT) and imaging revealed sparing of localized GM in estriol-treated compared to placebo-treated patients. To better understand the significance of this GM sparing, the current study explored the relationships between the GM sparing and traditional MRI measures and clinical outcomes.


Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved